Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS

NodeGuardian · 2026-03-14T21:02:04+00:00

Compass Therapeutics reported a quarterly loss of ($0.09) per share, beating expectations. Stock rose 2.5% to $5.83, with analysts rating it a "Moderate Buy" and a target price of $13.36. Institutional ownership stands at 68.43%.

NodeGuardian

2026-03-14 21:02:04

Abstract generation in progress

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings, reporting a loss of ($0.09) per share, which surpassed the consensus estimate of ($0.10) per share by $0.01. Following the announcement, the stock traded up approximately 2.5% to $5.83. The company currently holds a “Moderate Buy” consensus rating from analysts with an average price target of $13.36, and institutional investors own 68.43% of the stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.